{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-149921","form_type":"8-K","ticker":"LONA","cik":"0001620463","company_name":"LeonaBio, Inc.","filed_at":"2023-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.695649+00:00","generated_at":"2026-06-14T18:16:29.506456+00:00","sec_items":["5.02","5.07","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Athira Pharma appoints Andrew Gengos as CFO and CBO; Glenna Mileson retires","bullets":["Andrew Gengos appointed CFO and CBO effective May 18, 2023, replacing Glenna Mileson who is retiring after eight years.","Gengos receives $465,000 base salary, 40% bonus target, 400,000 stock options, and 10,000 RSUs tied to LIFT trial milestones.","Mileson will remain as transitional employee until June 16, 2023, then may serve as consultant at $3,500/month for up to 10 hours.","Stockholders elected Class III directors Kelly Romano and James Johnson; ratified Ernst & Young as auditor."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-149921","json":"https://secwatch.observer/filing/0001193125-23-149921.json","markdown":"https://secwatch.observer/filing/0001193125-23-149921.md","text":"https://secwatch.observer/filing/0001193125-23-149921.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1620463/000119312523149921/0001193125-23-149921-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1620463/000119312523149921/d457287d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T18:16:29.506456+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2dff92aeae","claim":"Glenna Mileson resigned as Chief Financial Officer at LeonaBio, Inc..","evidence_excerpt":"Glenna Mileson, the Company’s Chief Financial Officer, resigned from her position as Chief Financial Officer on May 18, 2023 effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1620463/000119312523149921/0001193125-23-149921-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"ba3b632536","claim":"Andrew Gengos was appointed as Chief Financial Officer and Chief Business Officer at LeonaBio, Inc..","evidence_excerpt":"the Company’s board of directors (the “Board”) appointed Andrew Gengos as the Company’s Chief Financial Officer and Chief Business Officer, effective May 18, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1620463/000119312523149921/0001193125-23-149921-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer and Chief Business Officer"}],"fact_type":"executive_change"},{"claim_id":"34d0158c117649e80929f5e724c3996ed52c4a01","claim":"LeonaBio, Inc. shareholders approved Election of Class III Directors at the 2023-05-18 meeting.","evidence_excerpt":"Proposal No. 1 – Election of Class III Directors The stockholders elected the two candidates nominated by the Company’s Board of Directors (the “Board”) to serve as directors of the Company until the annual meeting of stockholders to be held in 2026 or until their successors are elected and qualified. The following sets forth the results of the voting with respect to each candidate: Nominees of the Board For Withhold Broker Non-Votes Kelly A. Romano 13,993,414 3,466,402 9,303,812 James A. Johnson 14,519,313 2,940,503 9,303,812","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1620463/000119312523149921/0001193125-23-149921-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-18"}],"fact_type":"shareholder_vote"},{"claim_id":"ea846876c7d3b978b4d2fcaf2314e5b749556be3","claim":"LeonaBio, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-05-18 meeting.","evidence_excerpt":"Proposal No. 2 – Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023. The following sets forth the results of the voting with respect to this proposal: For Against Abstain Broker Non-Votes 26,704,561 39,131 19,936 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1620463/000119312523149921/0001193125-23-149921-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-18"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}